Professor Shahneen Sandhu is a Consultant Medical Oncologist and researcher in the Melanoma and Uro-oncology units at the Peter MacCallum Cancer Centre. She is the Research Lead for the Melanoma Medical Oncology Service.

Professor Sandhu obtained a medical degree from the University of Melbourne, completed her specialist medical oncology training at Peter Mac in 2007 and then subsequently undertook a translational research fellowship at the Royal Marsden Hospital and Institute of Cancer Research’s Drug Development Unit in London, UK between 2007 and 2012. This fellowship involved clinical and translational research with a specific focus on co-development of novel biomarkers and therapeutics for prostate cancer.

Professor Sandhu sits on multiple international advisory panels and has been principal investigator on multiple investigator-initiated and practise changing registration studies in melanoma and prostate cancer. She leads clinical, translational and laboratory research in skin cancers and prostate cancer with a major focus on designing and conducting biologically driven clinical trials to translate laboratory findings into new clinical treatments and studying biomarkers of response and resistance to treatment.

Over her career to date, Professor Sandhu has been a recipient of multiple awards to support her research and has published over 218 peer-reviewed research articles including in the following journals: New England Journal of Medicine, Journal of Clinical Oncology, Cancer Cell, Cancer Discovery, Lancet Oncology, Annals of Oncology and others.

Disclosures: Doctors often work with pharmaceutical companies and other organisations outside of Peter Mac, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. As a commitment to transparency, Professor Sandhu discloses the following relationships and financial interests:

• Consulting and advisory roles: Abbvie, AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Janssen, AdvanCell and Skyline Diagnostics
• Honoraria (funds directed to Peter Mac): Abbvie, AstraZeneca, Bristol-Myers Squibb, Janssen, Merck, Merck Serono, Novartis, AdvanCell and Skyline Diagnostics
• Equity (personal): AdvanCell
• Research funding for investigator-initiated research (funds directed to Peter Mac): Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Novartis, Pfizer, and Senhwa Biosciences